NAUT
Nautilus Biotechnology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.73
−13.06%Next report
Analyst consensus
- Next report date
- Feb 25, 2027
- EPS estimate
- -$0.15
- Revenue estimate
- $262.5K
Latest reported
- Last report date
- Oct 27, 2026
- EPS actual
- -$0.12
- EPS estimate
- -$0.14
- Revenue actual
- $234.0K
- Revenue estimate
- $206.3K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 12
- EPS misses (12Q)
- 0
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +18.2%
- Revenue beats (12Q)
- 2
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $3.75
- PT range
- $3.50 – $4.00
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Oct 27, 2026 | -$0.14 | -$0.12 | Beat 14.29% | $234.0K |
| Jul 28, 2026 | -$0.14 | -$0.11 | Beat 18.52% | $190.0K |
| Apr 28, 2026 | -$0.14 | -$0.12 | Beat 17.24% | — |
| Jul 31, 2025 | -$0.15 | -$0.12 | Beat 22.58% | — |
| Feb 26, 2025 | -$0.16 | -$0.14 | Beat 12.50% | $9.6M |
| Apr 30, 2024 | -$0.16 | -$0.15 | Beat 6.25% | — |
| Feb 28, 2024 | -$0.16 | -$0.14 | Beat 12.50% | $8.2M |
| Oct 31, 2023 | -$0.18 | -$0.13 | Beat 27.78% | — |
| Aug 2, 2023 | -$0.17 | -$0.13 | Beat 23.53% | — |
| May 2, 2023 | -$0.16 | -$0.12 | Beat 25.00% | — |
| Feb 23, 2023 | -$0.15 | -$0.11 | Beat 26.67% | — |
| Nov 1, 2022 | -$0.14 | -$0.11 | Beat 21.43% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 25, 2027